New research: Lenvatinib vs sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a phase 3 trial

Linda Howard General news

Our CEO, Stacie Hudgens, is co-author of a manuscript published by The Lancet on June 1:

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Image

Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The aim of this study was to evaluate the effect of treatment with lenvatinib versus sorafenib on HRQOL.

View full publication here 

Access via The Lancet here